Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

SFDA Releases 2011 Drug and Clinical Trial Approval Report

publication date: Oct 11, 2012
View a Printer Friendly version of this page, allowing you to print the page.
In 2011, the SFDA issued fewer drug approvals and allowed a smaller number of clinical trials than the year earlier. On the other hand, the agency received a larger number of applications for drug registration. In total, the SFDA approved 718 drug registrations last year, a reduction of 29% from the year earlier. In addition, the agency approved 621 applications to begin clinical trials, a decline of 32% from 2010. However,the 3620 applications for drug registrations were up 18% over 2010. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China